A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

NCT ID: NCT06961747

Last Updated: 2025-08-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-09
• Study Completion Date: 2026-07-22

Brief Summary

The purpose of this study is to assess the steady state (SS) concentrations of zilucoplan (ZLP) and its major metabolites in mature breast milk of healthy study participants following injection of repeated once-daily doses of ZLP.

Conditions

Healthy Participants

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Zilucoplan

Study participants enrolled in this arm will receive daily ZLP injections.

Group Type: EXPERIMENTAL

Zilucoplan

Intervention Type: DRUG

Dose formulation: Solution for injection. Route of administration: Subcutaneous injection.

Interventions

Zilucoplan

Dose formulation: Solution for injection. Route of administration: Subcutaneous injection.

Intervention Type: DRUG

Other Intervention Names

RA101495

Eligibility Criteria

Inclusion Criteria

• Study participant must be minimum 18 years at the time of signing the Informed consent form (ICF)
• Study participant is overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
• Study participant is lactating and will be at least 6 weeks postpartum on Day 1 of the study
• Study participant has already planned, prior to having knowledge of this study, to cease breast milk feeding (by any means) in relation to her current period of lactation
• Study participant agrees to cease breast milk feeding by Day 1 of the study and to not resume breast milk feeding (by any means and of any infant) or donate breast milk following study end for the remainder of her current period of lactation
• Study participant is up to date with vaccinations against meningococcal bacteria (serogroups A, C, W, Y, and B) at least 2 weeks before the first administration of study medication according to the current (at the time of study participant consent) Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccinations in patients receiving a complement inhibitor
• Study participant is capable of giving signed informed consent

Exclusion Criteria

• Study participant has a history or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study medication; or interfering with the interpretation of data
• Study participant has any medical, obstetrical, or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study
• Study participant has bilirubin >1.0xULN (isolated bilirubin <1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). For participants with a Baseline result >ULN for total bilirubin, a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the eCRF
• Study participant has a history of lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
• Study participant has current or recent systemic infection within 2 weeks before the first administration of study medication or infection requiring intravenous antibiotics within 4 weeks before the first administration of study medication. Note: Study participants with mastitis at Screening that does not meet the criteria for clinically significant infection may be rescreened after the infection is completely resolved
• Study participant has a prior history of meningococcal disease
• Study participant has presence of hepatitis B surface antigen at Screening or within 3 months prior to dosing
• Study participant has a positive hepatitis C antibody test result at Screening or within 3 months prior to starting study medication
• Study participant has a positive hepatitis C RNA test result at Screening or within 3 months prior to first dose of study medication
• Study participant has a positive prestudy drug and/or alcohol screen
• Study participant has a positive human immunodeficiency virus antibody test at the Screening Visit
• Study participant has a positive syphilis test at the Screening Visit

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

UCB Biopharma SRL

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

UCB Cares

Role: STUDY_DIRECTOR

001 844 599 2273

Locations

UP0137 2

San Antonio, Texas, United States

Site Status: RECRUITING

UP0137 1

Salt Lake City, Utah, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

UCB Cares

Role: CONTACT

ucbcares@ucb.com

+18445992273

Other Identifiers

UP0137

Identifier Type: -

Identifier Source: org_study_id